Volume 1 · Issue 1 · July–September 2026
Current issue · July–September 2026
Systematic Review · e0001
Personalized microbiome biotherapeutics may tailor donor, product, recipient, ecological conditioning, or monitoring. This review assessed human evidence across recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, ulcerative colitis, and multidrug-resistant organism (MDRO) decolonization, distinguishing validated personalization from protocol standardization.
Systematic Review · e0002
Circulating tumor DNA (ctDNA) may guide adjuvant treatment after curative-intent therapy and support multicancer early detection (MCED), but prognostic accuracy and clinical utility are distinct.
Systematic Review · e0003
Incretin treatment selection should consider comorbidity, expected weight loss, durability, route, tolerability, body composition, and access. This review evaluated phenotype-oriented evidence for semaglutide, tirzepatide, and emerging oral or multi-agonist therapies.
Systematic Review · e0004
Personalized bacteriophage therapy uses preparations selected, adapted or engineered against a patient’s bacterial isolate. This review aimed to synthesize human evidence on personalized or strain-matched therapy and distinguish it from fixed-product randomized evidence.
Evidence Map · e0005
Multimodal and generative artificial intelligence systems are increasingly evaluated for clinical decision support, but technical performance does not establish patient benefit. This review aimed to map clinical evidence while separating multimodal systems from adjacent generative decision support.